IDiyas

For the Inventor, By the Inventor

Vestavia, AL, United States of America

Weihe Zhang

USPTO Granted Patents = 39 

 

Average Co-Inventor Count = 5.7

ph-index = 5

Forward Citations = 107(Granted Patents)


Location History:

  • Chapel Hill, NC (US) (2016 - 2017)
  • Vestavia, AL (US) (2017 - 2022)
  • Vestavia Hills, AL (US) (2022 - 2024)

Company Filing History:

goldMedal27 out of 81 
 
Biocryst Pharmaceuticals, Inc.
 patents
silverMedal11 out of 1,269 
 
University of North Carolina at Chapel Hill
 patents
bronzeMedal1 out of 1 
 
Meryx, Inc.
 patent

Years Active: 2016-2025

where 'Filed Patents' based on already Granted Patents

39 patents (USPTO):
1. 12485109 - Pyrrolo 12.3-dipyrimidine compounds and analogues thereof (2025-12-02),
2. 12275737 - Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications (2025-04-14),
3. 12162838 - Human plasma kallikrein inhibitors (2024-12-10),
4. 12116346 - Human plasma kallikrein inhibitors (2024-10-15),
5. 12054492 - Imidazole-containing inhibitors of ALK2 kinase (2024-08-06),
6. 12043610 - Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors (2024-07-23),
7. 11866418 - Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors (2024-01-09),
8. 11807605 - Human plasma kallikrein inhibitors (2023-11-07),
9. 11708347 - Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors (2023-07-25),
10. 11708333 - Human plasma kallikrein inhibitors (2023-07-25),
11. 11708332 - Human plasma kallikrein inhibitors (2023-07-25),
12. 11685721 - Human plasma kallikrein inhibitors (2023-06-27),
13. 11661426 - Imidazole-containing inhibitors of ALK2 kinase (2023-05-30),
14. 11618731 - Prodrugs of kallikrein inhibitors (2023-04-04),
15. 11559515 - Indole compounds and analogues thereof (2023-01-24),

Title: Weihe Zhang - Innovator in Human Plasma Kallikrein Inhibitors

Introduction

Weihe Zhang, based in Vestavia, Alabama, is a prolific inventor with an impressive portfolio of 37 patents. His work primarily focuses on the development of innovative pharmaceuticals, particularly in the area of human plasma kallikrein inhibitors.

Latest Patents

Among his most recent patents are notable compounds designed to inhibit human plasma kallikrein. These compounds are vital in addressing various medical conditions and represent advancements in therapeutic options for patients.

Career Highlights

Zhang has made significant contributions to the field of biochemistry through his work at respected institutions. He has held key roles at Biocryst Pharmaceuticals, Inc. and the University of North Carolina at Chapel Hill, where he has fostered innovation and research excellence.

Collaborations

Throughout his career, Weihe Zhang has collaborated with esteemed colleagues, including Pravin L. Kotian and Yarlagadda Sudhakara Babu. These partnerships have facilitated the advancement of research and development in the pharmaceutical industry.

Conclusion

Weihe Zhang’s extensive experience and dedication to the development of human plasma kallikrein inhibitors reflect his vital role in medical innovation. With a track record of impactful patents and collaborations, he continues to contribute significantly to the field, enhancing therapeutic possibilities for many.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…